An inhibitor of 11-β hydroxysteroid dehydrogenase type 1 (PF915275) alleviates nonylphenol-induced hyperadrenalism and adiposity in rat and human cells

Autor: Ling-Ling Chang, Wan-Song Alfred Wun, Paulus S. Wang

Publikováno v: BMC Pharmacology and Toxicology, Vol 19, Iss 1, Pp 1-17 (2018)

Abstract Background Nonylphenol (NP) is an environmental endocrine-disrupting chemical (EDC) detected in human cord blood and milk. NP exposure in developmental periods results in hyperadrenalism and increasing 11β-hydroxysteroid dehydrogenase I (11

Externí odkaz: https://doaj.org/article/44f58fac26c84c53ac14534885753f2c

LYMPHOCYTIC HYPOPHYSITIS MASQUERADING AS TRANSIENT SECONDARY HYPERADRENALISM FOLLOWED BY PANHYPOPITUITARISM

Autor: Tarun Sharma, Dhiraj Kapoor, Bhagwan Das Negi, Sayan Malakar, Kailash Nath Sharma

Publikováno v: Volume 5, Issue 2, Mar - Apr 2019. 5:106-108

Lymphocytic hypophysitis (LH) is a rare inflammatory disease of the pituitary gland. This condition strikingly shows femalepreponderance and commonly affects women during pregnancy or in the post-partum period. It’s a clinical presentation and radi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5c5538771c3ccc5f43818b6a9bda0bd4
https://doi.org/10.32677/ijcr.2019.v05.i02.004

Effects of Nonylphenol on Hyperadrenalism and Metabolism in Male Rats

Autor: Ling-Ling Chang, Paulus S. Wang

Publikováno v: Journal of Metabolic Investigation. 1

Nonylphenol (NP) is an environmental endocrine-disrupting chemical (EDC) that has been detected in human cord blood and milk. It is unavoidable that human fetus and infant exposure to this environmental contaminant. We previously observed that develo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5fc4851181e4a39bb9017e4607f84601
https://doi.org/10.14800/jmi.1379

Cannabinoids and Schizophrenia: Therapeutic Prospects

Autor: Geoffrey Guy, V. Di Marzo, Philip Robson

Publikováno v: Current pharmaceutical design
20 (2014): 2194–2204. doi:10.2174/13816128113199990427
info:cnr-pdr/source/autori:Robson P.J.; Guy G.W.; Di Marzo V./titolo:Cannabinoids and schizophrenia: Therapeutic prospects/doi:10.2174%2F13816128113199990427/rivista:Current pharmaceutical design (Print)/anno:2014/pagina_da:2194/pagina_a:2204/intervallo_pagine:2194–2204/volume:20

Approximately one third of patients diagnosed with schizophrenia do not achieve adequate symptom control with standard antipsychotic drugs (APs). Some of these may prove responsive to clozapine, but non-response to APs remains an important clinical p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cbda17f7259850764a9f1bba920f1ab2
https://doi.org/10.2174/13816128113199990427

In utero and neonate exposure to nonylphenol develops hyperadrenalism and metabolic syndrome later in life. I. First generation rats (F1)

Autor: Paulus S. Wang, Ling-Ling Chang, Wan-Song A. Wun

Publikováno v: Toxicology. 301:40-49

Nonylphenol (NP) is an endocrine disruptor (ENDR). It is a chemical associated with the production and degradation of nonylphenol ethoxylates (NPE). NPE is widely used as nonionic surfactants. Previously, we observed that NP increased the production

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c21dbd0594e9efb0fa614d7483244436
https://doi.org/10.1016/j.tox.2012.06.017